PT  - JOURNAL ARTICLE
AU  - Sergey E. Borisov
AU  - Keertan Dheda
AU  - Martin Enwerem
AU  - Rodolfo Romero Leyet
AU  - Lia D'Ambrosio
AU  - Rosella Centis
AU  - Giovanni Sotgiu
AU  - Simon Tiberi
AU  - Jan-Willem Alffenaar
AU  - Andrey Maryandyshev
AU  - Evgeny Belilovski
AU  - Shashank Ganatra
AU  - Alena Skrahina
AU  - Onno Akkerman
AU  - Alena Aleksa
AU  - Rohit Amale
AU  - Janina Artsukevich
AU  - Judith Bruchfeld
AU  - Jose A. Caminero
AU  - Isabel Carpena Martinez
AU  - Luigi Codecasa
AU  - Margareth Dalcolmo
AU  - Justin Denholm
AU  - Paul Douglas
AU  - Raquel Duarte
AU  - Aliasgar Esmail
AU  - Mohammed Fadul
AU  - Alexey Filippov
AU  - Lina Davies Forsman
AU  - Mina Gaga
AU  - Julia-Amaranta Garcia-Fuertes
AU  - José-María García-García
AU  - Gina Gualano
AU  - Jerker Jonsson
AU  - Heinke Kunst
AU  - Jillian S. Lau
AU  - Barbara Lazaro Mastrapa
AU  - Jorge Lazaro Teran Troya
AU  - Selene Manga
AU  - Katerina Manika
AU  - Pablo González Montaner
AU  - Jai Mullerpattan
AU  - Suzette Oelofse
AU  - Martina Ortelli
AU  - Domingo Juan Palmero
AU  - Fabrizio Palmieri
AU  - Antonella Papalia
AU  - Apostolos Papavasileiou
AU  - Marie-Christine Payen
AU  - Emanuele Pontali
AU  - Carlos Robalo Cordeiro
AU  - Laura Saderi
AU  - Tsetan Dorji Sadutshang
AU  - Tatsiana Sanukevich
AU  - Varvara Solodovnikova
AU  - Antonio Spanevello
AU  - Sonam Topgyal
AU  - Federica Toscanini
AU  - Adrian R. Tramontana
AU  - Zarir Farokh Udwadia
AU  - Pietro Viggiani
AU  - Veronica White
AU  - Alimuddin Zumla
AU  - Giovanni Battista Migliori
TI  - Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study
AID  - 10.1183/13993003.00387-2017
DP  - 2017 May 01
TA  - European Respiratory Journal
PG  - 1700387
VI  - 49
IP  - 5
4099  - http://erj.ersjournals.com/content/49/5/1700387.short
4100  - http://erj.ersjournals.com/content/49/5/1700387.full
SO  - Eur Respir J2017 May 01; 49
AB  - Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92–280) days and exposed to bedaquiline for 168 (86–180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively).Sputum smear and culture conversion rates in MDR-TB cases were 63.6% and 30.1%, respectively at 30 days, 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of treatment. The median (IQR) time to smear and culture conversion was 34 (30–60) days and 60 (33–90) days. Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed. Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died, having electrocardiographic abnormalities that were probably non-bedaquiline related.Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions. Bedaquiline is safe and effective in treating MDR- and XDR-TB patients http://ow.ly/6MWK30adHkw